Larimar Therapeutics (FRA:ZA71) Buyback Yield %: -27.24 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZA71 Larimar Therapeutics Inc FRA:ZA71
41 GF Score
Price €3.22
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Buyback Yield %?

Larimar Therapeutics FRA:ZA71 -1.23% 41 Buyback Yield % is -27.24 as of Jul. 16, 2026. GuruFocus rates FRA:ZA71 with a GF Score™ of 41/100. The stock has 2 warning signs investors should review. Among 740 Biotechnology companies, Larimar Therapeutics ranks worse than 75.54% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Larimar Therapeutics's current buyback yield was -27.24%.

Larimar Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Larimar Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Larimar Therapeutics Buyback Yield % Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial -10.63 -44.14 0.00 -65.44 -20.15

Larimar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.00 0.00 -20.56 -23.12

FRA:ZA71 vs XFOR, CMPX, PROK: Buyback Yield % Comparison

For the Biotechnology subindustry, Larimar Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Larimar Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's Buyback Yield % falls into.


FRA:ZA71
41GF Score
Larimar Therapeutics Inc FRA:ZA71
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Larimar Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Larimar Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 55.583) / 275.8588
=-20.15%

Larimar Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 93.507) / 386.44476
=-24.20%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -27.24 mean?
Larimar Therapeutics (FRA:ZA71) has a Buyback Yield % of -27.24 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Larimar Therapeutics and its competitors. According to the industry distribution chart, Larimar Therapeutics ranks #559 out of 740 companies in the Biotechnology industry, placing it in the top 75.5%.
Is Larimar Therapeutics' Buyback Yield % too high?
Larimar Therapeutics' current Buyback Yield % is -27.24. Based on the distribution chart, Larimar Therapeutics ranks #559 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Larimar Therapeutics has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Buyback Yield % compare to XFOR and CMPX?
According to the Biotechnology industry distribution chart, Larimar Therapeutics ranks #559 out of 740 companies for Buyback Yield %. This places Larimar Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Larimar Therapeutics and its competitors. Larimar Therapeutics's current Buyback Yield % is -27.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (FRA:ZA71) has a current Buyback Yield % of -27.24. The current Buyback Yield % is -27.24. Larimar Therapeutics' overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Larimar Therapeutics (FRA:ZA71), the current Buyback Yield % is -27.24 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges LRMR:USA
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
41GF Score

Get the complete analysis for FRA:ZA71

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.22
Price